These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 36364911)

  • 1. Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.
    Quiroga B; Torra R
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tolvaptan, a vasopressin V
    Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
    Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
    Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E; Rodas L; Blasco M; Molina A; Quintana L
    Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
    Zhou JX; Torres VE
    Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
    Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
    Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
    J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A
    Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
    Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
    Torres VE
    Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ; Koorevaar IW; van Gastel MDA; van Goor H; Hallows KR; Heerspink HL; Li H; Leonhard WN; Peters DJM; Qiu J; Touw DJ; Gansevoort RT; Meijer E
    Clin J Am Soc Nephrol; 2022 Apr; 17(4):507-517. PubMed ID: 35314480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease.
    Ackley W; Dahl NK; Park M
    Adv Kidney Dis Health; 2023 May; 30(3):228-235. PubMed ID: 37088525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
    J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ADPKD treatment: Tolvaptan and Octreotide].
    Galliani M; Chicca S; Vitaliano E; Moscaritolo E; Calvaruso L; Iorio F; Paone A
    G Ital Nefrol; 2019 Dec; 36(6):. PubMed ID: 31830392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.